TABLE 1.
Demographic and clinical characteristicsa
| Characteristic | Valuesb for: |
|
|---|---|---|
| Total cohort (n = 259) | Patients with MDR Pseudomonas aeruginosa (n = 226) | |
| Age (yr) | 62 (52–72) | 62 (53, 72) |
| Age ≥65 yr | 106 (40.9) | 92 (40.7) |
| Male sex | 167 (64.5) | 142 (62.8) |
| Race | ||
| African American | 122 (47.1) | 116 (51.3) |
| Caucasian | 96 (37.1) | 78 (34.5) |
| Latino | 15 (5.8) | 11 (4.9) |
| Other | 26 (10.0) | 21 (0.3) |
| BMI | 27 (22–32) | 26 (22–32) |
| Obese (BMI, ≥30 kg/m2) | 84 (32.4) | 73 (32.3) |
| Underweight (BMI, <18.5 kg/m2) | 29 (11.2) | 26 (11.5) |
| Estimated CrCl (ml/min)c | 78 (45–129) | 78 (45–128) |
| CrCl, >50 ml/min | 172 (66.4) | 149 (65.9) |
| CrCl, 30–50 ml/min | 41 (15.8) | 35 (15.5) |
| CrCl, 15–29 ml/min | 21 (8.1) | 20 (8.8) |
| CrCl, <15 ml/min | 4 (1.5) | 4 (1.8) |
| Hemodialysis | 21 (8.1) | 18 (8.0) |
| Residence prior to admission | ||
| Community | 124 (47.9) | 104 (46.0) |
| Skilled nursing facility | 83 (32.0) | 80 (35.4) |
| Long-term acute care hospital | 4 (1.5) | 3 (1.3) |
| Inpatient rehabilitation facility | 8 (3.1) | 7 (3.1) |
| Transferred from outside hospital | 40 (15.4) | 32 (14.2) |
| Comorbid conditions | ||
| Diabetes | 109 (42.1) | 97 (42.9) |
| Heart Failure | 51 (19.7) | 46 (20.4) |
| COPD | 56 (21.6) | 51 (22.6) |
| Malignancy | 24 (9.3) | 22 (9.7) |
| Liver disease | 18 (6.9) | 15 (6.6) |
| Charlson comorbidity index score | 3 (2–5) | 4 (2–5) |
| Charlson comorbidity index score, >4 | 90 (34.7) | 82 (36.3) |
| Immunocompromised | 23 (8.9) | 18 (8.0) |
| MDR infection or colonization within 1 yr | 143 (55.2) | 129 (57.1) |
| Recent antibiotic exposure (≥24 h within 90 days) | 191 (73.7) | 173 (76.5) |
| Recent hospitalization (≥48 h within 90 days) | 177 (68.3) | 156 (69.0) |
| Recent surgery (within 30 days) | 39 (15.1) | 31 (13.7) |
| ICU at index culture | 131 (50.6) | 117 (51.8) |
| SOFA score | 5 (2–8) | 5 (3–8) |
| APACHE II score | 21 (12–27) | 21 (14–28) |
a
APACHE, Acute Physiological and Chronic Health Evaluation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; ICU, intensive care unit; LTAC, long-term acute care hospital; MDR, multidrug resistant; SOFA, sequential organ failure assessment.
b
All values represent n (%) or median (interquartile range).
c
Estimated by using the Cockroft Gault equation (46); creatinine measured within 24 h of first dose of ceftolozane-tazobactam.